Your browser doesn't support javascript.
loading
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.
Soffietti, Riccardo; Bettegowda, Chetan; Mellinghoff, Ingo K; Warren, Katherine E; Ahluwalia, Manmeet S; De Groot, John F; Galanis, Evanthia; Gilbert, Mark R; Jaeckle, Kurt A; Le Rhun, Emilie; Rudà, Roberta; Seoane, Joan; Thon, Niklas; Umemura, Yoshie; Weller, Michael; van den Bent, Martin J; Vogelbaum, Michael A; Chang, Susan M; Wen, Patrick Y.
Afiliação
  • Soffietti R; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
  • Bettegowda C; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Mellinghoff IK; Department of Neurology, Memorial Sloan Kettering Cancer Center New York, USA.
  • Warren KE; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Ahluwalia MS; Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA.
  • De Groot JF; Department of Neuro-Oncology, University of Texas, MD Anderson Cancer Center Houston, Houston, Texas, USA.
  • Galanis E; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Jaeckle KA; Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Le Rhun E; Departments of Neurology & Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Rudà R; Department of Neurology, Castelfranco Veneto/Treviso Hospital and Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.
  • Seoane J; Vall d'Hebron Institute of Oncology (VHIO) University Hospital, Universitat Autònoma de Barcelona, ICREA,CIBERONC, Barcelona, Spain.
  • Thon N; Division of Neuro-Oncology, Department of Neurosurgery, Ludwig Maximilians University School of Medicine, Munich, Germany.
  • Umemura Y; Division of Neuro-Oncology, Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
  • Weller M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • van den Bent MJ; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Vogelbaum MA; Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio, USA.
  • Chang SM; Division of Neuro-Oncology, University of California San Francisco, San Francisco, California, USA.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
Neuro Oncol ; 24(6): 855-871, 2022 06 01.
Article em En | MEDLINE | ID: mdl-34999836
ABSTRACT

BACKGROUND:

There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring.

METHODS:

The RANO (Response Assessment in Neuro-Oncology) group developed a multidisciplinary international Task Force to review the English literature on liquid biopsy in gliomas focusing on the most frequently used techniques, that is circulating tumor DNA, circulating tumor cells, and extracellular vesicles in blood and CSF.

RESULTS:

ctDNA has a higher sensitivity and capacity to represent the spatial and temporal heterogeneity in comparison to circulating tumor cells. Exosomes have the advantages to cross an intact blood-brain barrier and carry also RNA, miRNA, and proteins. Several clinical applications of liquid biopsies are suggested to establish a diagnosis when tissue is not available, monitor the residual disease after surgery, distinguish progression from pseudoprogression, and predict the outcome.

CONCLUSIONS:

There is a need for standardization of biofluid collection, choice of an analyte, and detection strategies along with rigorous testing in future clinical trials to validate findings and enable entry into clinical practice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Tumoral Circulante / Glioma / Células Neoplásicas Circulantes Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Tumoral Circulante / Glioma / Células Neoplásicas Circulantes Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article